{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:20:38Z","timestamp":1788776438665,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Relapse in patients with acute myeloid leukemia (AML) is common and is associated with a dismal prognosis. Treatment options are limited and the understanding of molecular response patterns is still challenging. We analyzed the clonal response patterns of 15 patients with relapsed\/refractory AML treated with selinexor in a phase II trial (SAIL). DNA was analyzed at three time points and showed a decline of mutated alleles in <jats:italic>FLT3<\/jats:italic>, <jats:italic>SF3B1<\/jats:italic>, and <jats:italic>TP53<\/jats:italic> under SAIL treatment. Overall survival (OS) was similar between patients with declining versus persisting clones. We show an interesting long-term course of a patient who relapsed after allogeneic stem cell transplantation (alloHCT) with SF3B1- and SRSF2-mutated AML and received selinexor as maintenance treatment for 4\u00a0years. Measurable residual disease (MRD) remained detectable for 2\u00a0weeks after donor lymphocyte infusion (DLI) in this patient and then remained negative under selinexor maintenance treatment. Selinexor was tolerated well and was stopped after 4\u00a0years of SAIL treatment. We present an exploratory study and identify subclonal patterns of patients treated with selinexor.<\/jats:p>","DOI":"10.1007\/s00277-022-05075-4","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T07:02:48Z","timestamp":1672210968000},"page":"323-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Molecular response patterns in relapsed\/refractory AML patients treated with selinexor and chemotherapy"],"prefix":"10.1007","volume":"102","author":[{"given":"Piroska","family":"Klement","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razif","family":"Gabdoulline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa-Kristin","family":"Dallmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Philine","family":"Wienecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kandziora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Teich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennett","family":"Heida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Funke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basem","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Chromik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Amberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Kebenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Schlipfenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Christine","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Modemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Janning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Theile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Deppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Kranich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-9044","authenticated-orcid":false,"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"issue":"13","key":"5075_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","volume":"79","author":"YY Syed","year":"2019","unstructured":"Syed YY (2019) Selinexor: first global approval. Drugs 79(13):1485\u20131494","journal-title":"Drugs"},{"issue":"5","key":"5075_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","volume":"18","author":"UH Gandhi","year":"2018","unstructured":"Gandhi UH, Senapedis W, Baloglu E, Unger TJ, Chari A, Vogl D et al (2018) Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin Lymphoma Myeloma Leuk 18(5):335\u2013345","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"5075_CR3","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","volume":"22","author":"P Ranganathan","year":"2016","unstructured":"Ranganathan P, Kashyap T, Yu X, Meng X, Lai TH, McNeil B et al (2016) XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase II\u03b1 to the nucleus. Clin Cancer Res 22(24):6142\u20136152","journal-title":"Clin Cancer Res"},{"issue":"12","key":"5075_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136\u20131152","journal-title":"N Engl J Med"},{"issue":"24","key":"5075_CR5","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","volume":"129","author":"R Garzon","year":"2017","unstructured":"Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M et al (2017) A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood 129(24):3165\u20133174","journal-title":"Blood"},{"key":"5075_CR6","doi-asserted-by":"crossref","unstructured":"Fiedler W, Chromik J, Amberg S, Kebenko M, Thol F, Schlipfenbacher V, et al (2020) A phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed\/refractory acute myeloid leukaemia. Br J Haematol 190(3):e169; e169-e173; e173","DOI":"10.1111\/bjh.16804"},{"key":"5075_CR7","doi-asserted-by":"crossref","unstructured":"Alexander TB, Lacayo NJ, Choi JK, Ribeiro RC, Pui C, Rubnitz JE (2016) Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia. J Clin Oncol 34(34):4094; 4094\u20134101; 4101","DOI":"10.1200\/JCO.2016.67.5066"},{"issue":"20","key":"5075_CR8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"8","key":"5075_CR9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00277-017-3027-5","volume":"96","author":"M Heuser","year":"2017","unstructured":"Heuser M, Gabdoulline R, L\u00f6ffeld P, Dobbernack V, Kreimeyer H, Pankratz M et al (2017) Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Ann Hematol 96(8):1361\u20131372","journal-title":"Ann Hematol"},{"issue":"16","key":"5075_CR10","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C et al (2018) Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 132(16):1703\u20131713","journal-title":"Blood"},{"key":"5075_CR11","doi-asserted-by":"crossref","unstructured":"Treff NR, Su J, Tao X, Northrop LE, Scott RT (2011) Single-cell whole-genome amplification technique impacts the accuracy of SNP microarray-based genotyping and copy number analyses. Mol Hum Reprod 17(6):335; 335\u2013343; 343","DOI":"10.1093\/molehr\/gaq103"},{"key":"5075_CR12","doi-asserted-by":"crossref","unstructured":"Engel NW, Reinert J, Borchert NM, Panagiota V, Gabdoulline R, Thol F, et al (2021) Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow. Ann Hematol 100(2):499; 499\u2013503; 503","DOI":"10.1007\/s00277-020-04313-x"},{"key":"5075_CR13","doi-asserted-by":"crossref","unstructured":"Zhang W, Ly C, Ishizawa J, Mu H, Ruvolo V, Shacham S, et al (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in -mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103(10):1642; 1642\u20131653; 1653","DOI":"10.3324\/haematol.2017.185082"},{"key":"5075_CR14","doi-asserted-by":"crossref","unstructured":"Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, et al (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11(1):4; 4","DOI":"10.1186\/s13045-017-0550-8"},{"key":"5075_CR15","doi-asserted-by":"crossref","unstructured":"Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, et al (2020) Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leuk Lymphoma 61(2):387; 387\u2013396; 396","DOI":"10.1080\/10428194.2019.1665664"},{"key":"5075_CR16","doi-asserted-by":"crossref","unstructured":"Turner JG, Dawson J, Sullivan DM (2012) Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83(8):1021; 1021\u20131032; 1032","DOI":"10.1016\/j.bcp.2011.12.016"},{"key":"5075_CR17","doi-asserted-by":"publisher","unstructured":"Richardson DR, Swoboda DM, Moore DT, Johnson SM, Chan O, Galeotti J,\u00a0Esparza S,\u00a0Hussaini MO,\u00a0Van Deventer H,\u00a0Foster MC, Coombs CC, Montgomery ND, Sallman DA, Zeidner JF\u00a0(2021) Genomic characteristics and prognostic significance of co-mutated ASXL1\/SRSF2 acute myeloid leukemia. Am J Hematol 96(4):462\u2013470.\u00a0 https:\/\/doi.org\/10.1002\/ajh.26110","DOI":"10.1002\/ajh.26110"},{"key":"5075_CR18","doi-asserted-by":"crossref","unstructured":"Sweet K, Bhatnagar B, D\u00f6hner H, Donnellan W, Frankfurt O, Heuser M, et al (2021) A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 62(13):3192; 3192\u20133203; 3203","DOI":"10.1080\/10428194.2021.1950706"},{"issue":"23","key":"5075_CR19","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209\u20132221","journal-title":"N Engl J Med"},{"issue":"15","key":"5075_CR20","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","volume":"119","author":"F Thol","year":"2012","unstructured":"Thol F, Kade S, Schlarmann C, L\u00f6ffeld P, Morgan M, Krauter J et al (2012) Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119(15):3578\u20133584","journal-title":"Blood"},{"issue":"7728","key":"5075_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL et al (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562(7728):526\u2013531","journal-title":"Nature"},{"key":"5075_CR22","unstructured":"Walker C, Panoskaltsis N, Crochiere M, Parcharidou A, Colis M, Enfield L, Shah J, Shacham S, Landesman Y (2020)\u00a0IDH2 P.R172K mutations in patients with acute myeloid leukemia (AML) may be associated with favorable response to selinexor treatment.\u00a0EHA Library 294403; EP484"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05075-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05075-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05075-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T09:09:33Z","timestamp":1675156173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05075-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5075"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05075-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutions of WF and MH received research funding from Karyopharm. The other authors have no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}